Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Dec, 2016 | Pages:
928 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Multiple Sclerosis - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Multiple Sclerosis - Pipeline Review, H2 2016, provides an overview of the Multiple Sclerosis (Central Nervous System) pipeline landscape. Multiple sclerosis (MS) is a potentially debilitating disease in which body's immune system eats away at the protective sheath (myelin) that covers nerves. Damage to myelin causes interference in the communication between brain, spinal cord and other areas of body. Symptoms include numbness or weakness in one or more limbs, double vision or blurring of vision, tingling or pain in parts of body, fatigue and slurred speech. The predisposing factors include age, gender, family history and certain infections. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Multiple Sclerosis - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Multiple Sclerosis (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Multiple Sclerosis (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Multiple Sclerosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 5, 9, 30, 32, 173, 36 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 4, 46 and 2 molecules, respectively. Multiple Sclerosis (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Multiple Sclerosis (Central Nervous System). - The pipeline guide reviews pipeline therapeutics for Multiple Sclerosis (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Multiple Sclerosis (Central Nervous System) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Multiple Sclerosis (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Multiple Sclerosis (Central Nervous System) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Multiple Sclerosis (Central Nervous System). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Multiple Sclerosis (Central Nervous System) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 Introduction 10 Multiple Sclerosis Overview 11 Therapeutics Development 12 Multiple Sclerosis - Therapeutics under Development by Companies 14 Multiple Sclerosis - Therapeutics under Investigation by Universities/Institutes 31 Multiple Sclerosis - Pipeline Products Glance 34 Multiple Sclerosis - Products under Development by Companies 38 Multiple Sclerosis - Products under Investigation by Universities/Institutes 58 Multiple Sclerosis - Companies Involved in Therapeutics Development 62 Multiple Sclerosis - Therapeutics Assessment 250 Drug Profiles 291 Multiple Sclerosis - Dormant Projects 839 Multiple Sclerosis - Discontinued Products 864 Multiple Sclerosis - Product Development Milestones 869 Appendix 891
List of Tables
Number of Products under Development for Multiple Sclerosis, H2 2016 48 Number of Products under Development for Multiple Sclerosis - Comparative Analysis, H2 2016 49 Number of Products under Development by Companies, H2 2016 51 Number of Products under Development by Companies, H2 2016 (Contd..1) 52 Number of Products under Development by Companies, H2 2016 (Contd..2) 53 Number of Products under Development by Companies, H2 2016 (Contd..3) 54 Number of Products under Development by Companies, H2 2016 (Contd..4) 55 Number of Products under Development by Companies, H2 2016 (Contd..5) 56 Number of Products under Development by Companies, H2 2016 (Contd..6) 57 Number of Products under Development by Companies, H2 2016 (Contd..7) 58 Number of Products under Development by Companies, H2 2016 (Contd..8) 59 Number of Products under Development by Companies, H2 2016 (Contd..9) 60 Number of Products under Development by Companies, H2 2016 (Contd..10) 61 Number of Products under Development by Companies, H2 2016 (Contd..11) 62 Number of Products under Development by Companies, H2 2016 (Contd..12) 63 Number of Products under Development by Companies, H2 2016 (Contd..13) 64 Number of Products under Development by Companies, H2 2016 (Contd..14) 65 Number of Products under Development by Companies, H2 2016 (Contd..15) 66 Number of Products under Investigation by Universities/Institutes, H2 2016 67 Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 68 Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 69 Comparative Analysis by Late Stage Development, H2 2016 70 Comparative Analysis by Clinical Stage Development, H2 2016 71 Comparative Analysis by Early Stage Development, H2 2016 72 Comparative Analysis by Unknown Stage Development, H2 2016 73 Products under Development by Companies, H2 2016 74 Products under Development by Companies, H2 2016 (Contd..1) 75 Products under Development by Companies, H2 2016 (Contd..2) 76 Products under Development by Companies, H2 2016 (Contd..3) 77 Products under Development by Companies, H2 2016 (Contd..4) 78 Products under Development by Companies, H2 2016 (Contd..5) 79 Products under Development by Companies, H2 2016 (Contd..6) 80 Products under Development by Companies, H2 2016 (Contd..7) 81 Products under Development by Companies, H2 2016 (Contd..8) 82 Products under Development by Companies, H2 2016 (Contd..9) 83 Products under Development by Companies, H2 2016 (Contd..10) 84 Products under Development by Companies, H2 2016 (Contd..11) 85 Products under Development by Companies, H2 2016 (Contd..12) 86 Products under Development by Companies, H2 2016 (Contd..13) 87 Products under Development by Companies, H2 2016 (Contd..14) 88 Products under Development by Companies, H2 2016 (Contd..15) 89 Products under Development by Companies, H2 2016 (Contd..16) 90 Products under Development by Companies, H2 2016 (Contd..17) 91 Products under Development by Companies, H2 2016 (Contd..18) 92 Products under Development by Companies, H2 2016 (Contd..19) 93 Products under Investigation by Universities/Institutes, H2 2016 94 Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 95 Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 96 Products under Investigation by Universities/Institutes, H2 2016 (Contd..3) 97 Multiple Sclerosis - Pipeline by 2-BBB Medicines BV, H2 2016 98 Multiple Sclerosis - Pipeline by 4D Pharma Plc, H2 2016 99 Multiple Sclerosis - Pipeline by AB Science SA, H2 2016 100 Multiple Sclerosis - Pipeline by AbbVie Inc, H2 2016 101 Multiple Sclerosis - Pipeline by Abion Inc, H2 2016 102 Multiple Sclerosis - Pipeline by Ablynx NV, H2 2016 103 Multiple Sclerosis - Pipeline by Abzena Plc, H2 2016 104 Multiple Sclerosis - Pipeline by Acorda Therapeutics Inc, H2 2016 105 Multiple Sclerosis - Pipeline by Actelion Ltd, H2 2016 106 Multiple Sclerosis - Pipeline by Adamas Pharmaceuticals Inc, H2 2016 107 Multiple Sclerosis - Pipeline by Addex Therapeutics Ltd, H2 2016 108 Multiple Sclerosis - Pipeline by Adhaere Pharmaceuticals Inc, H2 2016 109 Multiple Sclerosis - Pipeline by Aegis Therapeutics LLC, H2 2016 110 Multiple Sclerosis - Pipeline by Affectis Pharmaceuticals AG, H2 2016 111 Multiple Sclerosis - Pipeline by AiCuris GmbH & Co KG, H2 2016 112 Multiple Sclerosis - Pipeline by Alkermes Plc, H2 2016 113 Multiple Sclerosis - Pipeline by Alpha Cancer Technologies Inc, H2 2016 114 Multiple Sclerosis - Pipeline by Amarna Therapeutics BV, H2 2016 115 Multiple Sclerosis - Pipeline by Anavex Life Sciences Corp, H2 2016 116 Multiple Sclerosis - Pipeline by Antisense Therapeutics Ltd, H2 2016 117 Multiple Sclerosis - Pipeline by Aphios Corp, H2 2016 118 Multiple Sclerosis - Pipeline by Apitope International NV, H2 2016 119 Multiple Sclerosis - Pipeline by ARA Healthcare Pvt Ltd, H2 2016 120 Multiple Sclerosis - Pipeline by Arena Pharmaceuticals Inc, H2 2016 121 Multiple Sclerosis - Pipeline by arGEN-X BV, H2 2016 122 Multiple Sclerosis - Pipeline by Argos Therapeutics Inc, H2 2016 123 Multiple Sclerosis - Pipeline by Arrien Pharmaceuticals LLC, H2 2016 124 Multiple Sclerosis - Pipeline by Artielle ImmunoTherapeutics Inc, H2 2016 125 Multiple Sclerosis - Pipeline by Astellas Pharma Inc, H2 2016 126 Multiple Sclerosis - Pipeline by Asterias Biotherapeutics Inc, H2 2016 127 Multiple Sclerosis - Pipeline by Atara Biotherapeutics Inc, H2 2016 128 Multiple Sclerosis - Pipeline by Athersys Inc, H2 2016 129 Multiple Sclerosis - Pipeline by Atlantic Bio Sci LLC, H2 2016 130 Multiple Sclerosis - Pipeline by Axxam SpA, H2 2016 131 Multiple Sclerosis - Pipeline by Baliopharm AG, H2 2016 132 Multiple Sclerosis - Pipeline by Bio-Cancer Treatment International Ltd, H2 2016 133 Multiple Sclerosis - Pipeline by BioAegis Therapeutics Inc, H2 2016 134 Multiple Sclerosis - Pipeline by BioApex sro, H2 2016 135 Multiple Sclerosis - Pipeline by Biocad, H2 2016 136 Multiple Sclerosis - Pipeline by Biocon Ltd, H2 2016 137 Multiple Sclerosis - Pipeline by Biogen Inc, H2 2016 138 Multiple Sclerosis - Pipeline by Biogenomics Ltd, H2 2016 139 Multiple Sclerosis - Pipeline by BioHealthonomics Inc, H2 2016 140 Multiple Sclerosis - Pipeline by Biokine Therapeutics Ltd, H2 2016 141 Multiple Sclerosis - Pipeline by Biomar Microbial Technologies, H2 2016 142 Multiple Sclerosis - Pipeline by Bioncotech Therapeutics SL, H2 2016 143 Multiple Sclerosis - Pipeline by Bionovis SA, H2 2016 144 Multiple Sclerosis - Pipeline by Bionure Farma SL, H2 2016 145 Multiple Sclerosis - Pipeline by Biovista Inc, H2 2016 146 Multiple Sclerosis - Pipeline by Bolder Biotechnology Inc, H2 2016 147 Multiple Sclerosis - Pipeline by BrainStorm Cell Therapeutics Inc, H2 2016 148 Multiple Sclerosis - Pipeline by Bristol-Myers Squibb Company, H2 2016 149 Multiple Sclerosis - Pipeline by C4X Discovery Holdings PLC, H2 2016 150 Multiple Sclerosis - Pipeline by CASI Pharmaceuticals Inc, H2 2016 151 Multiple Sclerosis - Pipeline by Catalyst Pharmaceuticals Inc, H2 2016 152 Multiple Sclerosis - Pipeline by Celgene Corp, H2 2016 153 Multiple Sclerosis - Pipeline by Cell Cure Neurosciences Ltd, H2 2016 154 Multiple Sclerosis - Pipeline by Cell2B Advanced Therapeutics SA, H2 2016 155 Multiple Sclerosis - Pipeline by Cellceutix Corp, H2 2016 156 Multiple Sclerosis - Pipeline by Cognosci Inc, H2 2016 157 Multiple Sclerosis - Pipeline by Coherus BioSciences Inc, H2 2016 158 Multiple Sclerosis - Pipeline by Commence Bio Inc, H2 2016 159 Multiple Sclerosis - Pipeline by Compugen Ltd, H2 2016 160 Multiple Sclerosis - Pipeline by Connexios Life Sciences Pvt Ltd, H2 2016 161 Multiple Sclerosis - Pipeline by Critical Outcome Technologies Inc, H2 2016 162 Multiple Sclerosis - Pipeline by CuraVac Inc, H2 2016 163 Multiple Sclerosis - Pipeline by Cyxone AB, H2 2016 164 Multiple Sclerosis - Pipeline by Daiichi Sankyo Company Ltd, H2 2016 165 Multiple Sclerosis - Pipeline by Dimerix Bioscience Pty Ltd, H2 2016 166 Multiple Sclerosis - Pipeline by Dong-A Socio Holdings Co Ltd, H2 2016 167 Multiple Sclerosis - Pipeline by Eisai Co Ltd, H2 2016 168 Multiple Sclerosis - Pipeline by Eli Lilly and Company, H2 2016 169 Multiple Sclerosis - Pipeline by Endece LLC, H2 2016 170 Multiple Sclerosis - Pipeline by Evgen Pharma Plc, H2 2016 171 Multiple Sclerosis - Pipeline by Evotec AG, H2 2016 172 Multiple Sclerosis - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016 173 Multiple Sclerosis - Pipeline by Flex Pharma Inc, H2 2016 174 Multiple Sclerosis - Pipeline by Forward Pharma A/S, H2 2016 175 Multiple Sclerosis - Pipeline by FPRT Bio Inc, H2 2016 176 Multiple Sclerosis - Pipeline by Gemac SA, H2 2016 177 Multiple Sclerosis - Pipeline by Genervon Biopharmaceuticals LLC, H2 2016 178 Multiple Sclerosis - Pipeline by GeNeuro SA, H2 2016 179 Multiple Sclerosis - Pipeline by Genzyme Corp, H2 2016 180 Multiple Sclerosis - Pipeline by GlaxoSmithKline Plc, H2 2016 181 Multiple Sclerosis - Pipeline by Glenmark Pharmaceuticals Ltd, H2 2016 182 Multiple Sclerosis - Pipeline by Glialogix Inc, H2 2016 183 Multiple Sclerosis - Pipeline by Hansa Medical AB, H2 2016 184 Multiple Sclerosis - Pipeline by Harbor Therapeutics Inc, H2 2016 185 Multiple Sclerosis - Pipeline by HitGen LTD, H2 2016 186 Multiple Sclerosis - Pipeline by Humabs BioMed SA, H2 2016 187 Multiple Sclerosis - Pipeline by Hutchison MediPharma Ltd, H2 2016 188 Multiple Sclerosis - Pipeline by Iltoo Pharma, H2 2016 189 Multiple Sclerosis - Pipeline by Immune Response BioPharma Inc, H2 2016 190 Multiple Sclerosis - Pipeline by Immune Therapeutics Inc, H2 2016 191 Multiple Sclerosis - Pipeline by ImmuNext Inc, H2 2016 192 Multiple Sclerosis - Pipeline by Immungenetics AG, H2 2016 193 Multiple Sclerosis - Pipeline by Inception Sciences Inc, H2 2016 194 Multiple Sclerosis - Pipeline by Innate Immunotherapeutics Ltd, H2 2016 195 Multiple Sclerosis - Pipeline by Inovio Pharmaceuticals Inc, H2 2016 196 Multiple Sclerosis - Pipeline by Io Therapeutics Inc, H2 2016 197 Multiple Sclerosis - Pipeline by Jyant Technologies Inc, H2 2016 198 Multiple Sclerosis - Pipeline by Kadimastem Ltd, H2 2016 199 Multiple Sclerosis - Pipeline by Kadmon Corp LLC, H2 2016 200 Multiple Sclerosis - Pipeline by KAHR medical Ltd, H2 2016 201 Multiple Sclerosis - Pipeline by KaloBios Pharmaceuticals Inc, H2 2016 202 Multiple Sclerosis - Pipeline by Kancera AB, H2 2016 203 Multiple Sclerosis - Pipeline by Kareus Therapeutics SA, H2 2016 204 Multiple Sclerosis - Pipeline by Karo Pharma AB, H2 2016 205 Multiple Sclerosis - Pipeline by Karyopharm Therapeutics Inc, H2 2016 206 Multiple Sclerosis - Pipeline by Kissei Pharmaceutical Co Ltd, H2 2016 207 Multiple Sclerosis - Pipeline by KPI Therapeutics Inc, H2 2016 208 Multiple Sclerosis - Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2016 209 Multiple Sclerosis - Pipeline by Lead Discovery Center GmbH, H2 2016 210 Multiple Sclerosis - Pipeline by LFB SA, H2 2016 211 Multiple Sclerosis - Pipeline by Lipocure Ltd, H2 2016 212 Multiple Sclerosis - Pipeline by MacroGenics Inc, H2 2016 213 Multiple Sclerosis - Pipeline by MAKScientific LLC, H2 2016 214 Multiple Sclerosis - Pipeline by Mapi Pharma Ltd, H2 2016 215 Multiple Sclerosis - Pipeline by Marathon Pharmaceuticals LLC, H2 2016 216 Multiple Sclerosis - Pipeline by MedAnnex Ltd, H2 2016 217 Multiple Sclerosis - Pipeline by MedDay SA, H2 2016 218 Multiple Sclerosis - Pipeline by Medestea Research & Production SpA, H2 2016 219 Multiple Sclerosis - Pipeline by MedImmune LLC, H2 2016 220 Multiple Sclerosis - Pipeline by Merck KGaA, H2 2016 221 Multiple Sclerosis - Pipeline by Meta-IQ ApS, H2 2016 222 Multiple Sclerosis - Pipeline by Mitochon Pharmaceuticals Inc, H2 2016 223 Multiple Sclerosis - Pipeline by Mitsubishi Tanabe Pharma Corp, H2 2016 224 Multiple Sclerosis - Pipeline by MorphoSys AG, H2 2016 225 Multiple Sclerosis - Pipeline by Mount Tam Biotechnologies Inc, H2 2016 226 Multiple Sclerosis - Pipeline by Neuralstem Inc, H2 2016 227 Multiple Sclerosis - Pipeline by Neuren Pharmaceuticals Ltd, H2 2016 228 Multiple Sclerosis - Pipeline by Neuronax SAS, H2 2016 229 Multiple Sclerosis - Pipeline by Neurotec Pharma SL, H2 2016 230 Multiple Sclerosis - Pipeline by New World Laboratories Inc, H2 2016 231 Multiple Sclerosis - Pipeline by Novartis AG, H2 2016 232 Multiple Sclerosis - Pipeline by NovImmune SA, H2 2016 233 Multiple Sclerosis - Pipeline by Nuevolution AB, H2 2016 234 Multiple Sclerosis - Pipeline by Ogeda SA, H2 2016 235 Multiple Sclerosis - Pipeline by Omeros Corp, H2 2016 236 Multiple Sclerosis - Pipeline by OncoImmune Inc, H2 2016 237 Multiple Sclerosis - Pipeline by Opexa Therapeutics Inc, H2 2016 238 Multiple Sclerosis - Pipeline by Oryzon Genomics SA, H2 2016 239 Multiple Sclerosis - Pipeline by OSE Immunotherapeutics, H2 2016 240 Multiple Sclerosis - Pipeline by Parvus Therapeutics Inc, H2 2016 241 Multiple Sclerosis - Pipeline by Peptinov SAS, H2 2016 242 Multiple Sclerosis - Pipeline by Pfenex Inc, H2 2016 243 Multiple Sclerosis - Pipeline by Pfizer Inc, H2 2016 244 Multiple Sclerosis - Pipeline by PharmaEssentia Corp, H2 2016 245 Multiple Sclerosis - Pipeline by PharmatrophiX Inc, H2 2016 246 Multiple Sclerosis - Pipeline by Pharmaxis Ltd, H2 2016 247 Multiple Sclerosis - Pipeline by Pieris Pharmaceuticals Inc, H2 2016 248 Multiple Sclerosis - Pipeline by Polleo Pharma Ltd, H2 2016 249 Multiple Sclerosis - Pipeline by ProNoxis AB, H2 2016 250 Multiple Sclerosis - Pipeline by Prothena Corp Plc, H2 2016 251 Multiple Sclerosis - Pipeline by Q Therapeutics Inc, H2 2016 252 Multiple Sclerosis - Pipeline by ReceptoPharm Inc, H2 2016 253 Multiple Sclerosis - Pipeline by RedHill Biopharma Ltd, H2 2016 254 Multiple Sclerosis - Pipeline by RegeneRx Biopharmaceuticals Inc, H2 2016 255 Multiple Sclerosis - Pipeline by Regenesance BV, H2 2016 256 Multiple Sclerosis - Pipeline by Renovo Neural Inc, H2 2016 257 Multiple Sclerosis - Pipeline by Resverlogix Corp, H2 2016 258 Multiple Sclerosis - Pipeline by ReveraGen BioPharma Inc, H2 2016 259 Multiple Sclerosis - Pipeline by Rigel Pharmaceuticals Inc, H2 2016 260 Multiple Sclerosis - Pipeline by Rodos BioTarget GmbH, H2 2016 261 Multiple Sclerosis - Pipeline by SanBio Inc, H2 2016 262 Multiple Sclerosis - Pipeline by Santhera Pharmaceuticals Holding AG, H2 2016 263 Multiple Sclerosis - Pipeline by Sareum Holdings Plc, H2 2016 264 Multiple Sclerosis - Pipeline by Sorrento Therapeutics Inc, H2 2016 265 Multiple Sclerosis - Pipeline by Symic Biomedical Inc, H2 2016 266 Multiple Sclerosis - Pipeline by Synthon Holdings BV, H2 2016 267 Multiple Sclerosis - Pipeline by Targazyme Inc, H2 2016 268 Multiple Sclerosis - Pipeline by Teikoku Pharma USA Inc, H2 2016 269 Multiple Sclerosis - Pipeline by Teva Pharmaceutical Industries Ltd, H2 2016 270 Multiple Sclerosis - Pipeline by Therapix Biosciences Ltd, H2 2016 271 Multiple Sclerosis - Pipeline by TikoMed AB, H2 2016 272 Multiple Sclerosis - Pipeline by Toleranzia AB, H2 2016 273 Multiple Sclerosis - Pipeline by Topas Therapeutics GmbH, H2 2016 274 Multiple Sclerosis - Pipeline by TxCell SA, H2 2016 275 Multiple Sclerosis - Pipeline by Vaccinex Inc, H2 2016 276 Multiple Sclerosis - Pipeline by Vakzine Projekt Management GmbH, H2 2016 277 Multiple Sclerosis - Pipeline by Virogenomics BioDevelopment Inc, H2 2016 278 Multiple Sclerosis - Pipeline by Vitae Pharmaceuticals Inc, H2 2016 279 Multiple Sclerosis - Pipeline by VivaCell Biotechnology Espana SL, H2 2016 280 Multiple Sclerosis - Pipeline by Xenetic Biosciences (UK) Ltd, H2 2016 281 Multiple Sclerosis - Pipeline by XL-protein GmbH, H2 2016 282 Multiple Sclerosis - Pipeline by Yungjin Pharm Co Ltd, H2 2016 283 Multiple Sclerosis - Pipeline by Zenith Capital Corp, H2 2016 284 Multiple Sclerosis - Pipeline by Zydus Cadila Healthcare Ltd, H2 2016 285 Assessment by Monotherapy Products, H2 2016 286 Assessment by Combination Products, H2 2016 287 Number of Products by Stage and Target, H2 2016 289 Number of Products by Stage and Mechanism of Action, H2 2016 305 Number of Products by Stage and Route of Administration, H2 2016 324 Number of Products by Stage and Molecule Type, H2 2016 326 Multiple Sclerosis - Dormant Projects, H2 2016 875 Multiple Sclerosis - Dormant Projects (Contd..1), H2 2016 876 Multiple Sclerosis - Dormant Projects (Contd..2), H2 2016 877 Multiple Sclerosis - Dormant Projects (Contd..3), H2 2016 878 Multiple Sclerosis - Dormant Projects (Contd..4), H2 2016 879 Multiple Sclerosis - Dormant Projects (Contd..5), H2 2016 880 Multiple Sclerosis - Dormant Projects (Contd..6), H2 2016 881 Multiple Sclerosis - Dormant Projects (Contd..7), H2 2016 882 Multiple Sclerosis - Dormant Projects (Contd..8), H2 2016 883 Multiple Sclerosis - Dormant Projects (Contd..9), H2 2016 884 Multiple Sclerosis - Dormant Projects (Contd..10), H2 2016 885 Multiple Sclerosis - Dormant Projects (Contd..11), H2 2016 886 Multiple Sclerosis - Dormant Projects (Contd..12), H2 2016 887 Multiple Sclerosis - Dormant Projects (Contd..13), H2 2016 888 Multiple Sclerosis - Dormant Projects (Contd..14), H2 2016 889 Multiple Sclerosis - Dormant Projects (Contd..15), H2 2016 890 Multiple Sclerosis - Dormant Projects (Contd..16), H2 2016 891 Multiple Sclerosis - Dormant Projects (Contd..17), H2 2016 892 Multiple Sclerosis - Dormant Projects (Contd..18), H2 2016 893 Multiple Sclerosis - Dormant Projects (Contd..19), H2 2016 894 Multiple Sclerosis - Dormant Projects (Contd..20), H2 2016 895 Multiple Sclerosis - Dormant Projects (Contd..21), H2 2016 896 Multiple Sclerosis - Dormant Projects (Contd..22), H2 2016 897 Multiple Sclerosis - Dormant Projects (Contd..23), H2 2016 898 Multiple Sclerosis - Dormant Projects (Contd..24), H2 2016 899 Multiple Sclerosis - Discontinued Products, H2 2016 900 Multiple Sclerosis - Discontinued Products (Contd..1), H2 2016 901 Multiple Sclerosis - Discontinued Products (Contd..2), H2 2016 902 Multiple Sclerosis - Discontinued Products (Contd..3), H2 2016 903 Multiple Sclerosis - Discontinued Products (Contd..4), H2 2016 90
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
